ABEO vs. QURE, ACRS, EQ, LUMO, ACRX, SLN, HROW, ALXO, DNTH, and ANAB
Should you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include uniQure (QURE), Aclaris Therapeutics (ACRS), Equillium (EQ), Lumos Pharma (LUMO), AcelRx Pharmaceuticals (ACRX), Silence Therapeutics (SLN), Harrow (HROW), ALX Oncology (ALXO), Dianthus Therapeutics (DNTH), and AnaptysBio (ANAB). These companies are all part of the "medical" sector.
uniQure (NASDAQ:QURE) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk, community ranking and institutional ownership.
uniQure received 122 more outperform votes than Abeona Therapeutics when rated by MarketBeat users. Likewise, 70.70% of users gave uniQure an outperform vote while only 70.36% of users gave Abeona Therapeutics an outperform vote.
Abeona Therapeutics has a net margin of 0.00% compared to Abeona Therapeutics' net margin of -1,562.22%. Abeona Therapeutics' return on equity of -121.60% beat uniQure's return on equity.
uniQure has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.
In the previous week, Abeona Therapeutics had 10 more articles in the media than uniQure. MarketBeat recorded 13 mentions for Abeona Therapeutics and 3 mentions for uniQure. Abeona Therapeutics' average media sentiment score of 1.25 beat uniQure's score of 0.92 indicating that uniQure is being referred to more favorably in the media.
78.8% of uniQure shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 4.7% of uniQure shares are owned by company insiders. Comparatively, 5.3% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Abeona Therapeutics has lower revenue, but higher earnings than uniQure. Abeona Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.
uniQure currently has a consensus price target of $24.75, indicating a potential upside of 428.85%. Abeona Therapeutics has a consensus price target of $21.00, indicating a potential upside of 398.81%. Given Abeona Therapeutics' higher possible upside, equities research analysts plainly believe uniQure is more favorable than Abeona Therapeutics.
Summary
uniQure and Abeona Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Abeona Therapeutics Competitors List
Related Companies and Tools
